Myeloproliferative neoplasm natural history, complications, and prognosis

Revision as of 14:16, 23 October 2015 by Mohamad Alkateb (talk | contribs)
Jump to navigation Jump to search

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm natural history, complications, and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm natural history, complications, and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm natural history, complications, and prognosis

on Myeloproliferative neoplasm natural history, complications, and prognosis

Myeloproliferative neoplasm natural history, complications, and prognosis in the news

Blogs on Myeloproliferative neoplasm natural history, complications, and prognosis

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm natural history, complications, and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

If left untreated, patients with myeloproliferative neoplasm may progress to develop weight loss, fever, and night sweats. Common complications of myeloproliferative neoplasm include splenomegaly, bleeding, and thrombosis. Prognosis is generally good with treatment, and the 3-year survival rate of patients with myeloproliferative neoplasm is approximately 35%.[1][2]


Natural History

Complications

Prognosis

When properly diagnosed and carefully managed, some patients may survive for many years, depending on the specific disease they have. Recent advancements in CML treatment such as IFN alpha, bone marrow transplantation and recent development of an agent that inhibits the tyrosine kinase function of the BCR-ABL fusion protein, have substantially increased the life expectancy for patients with CML, so the median survival rates of 5-7 years are commonly reported. If similar mechanisms of pathogenesis do exist in the other MPNs, tyrosine kinase inhibitors or similar agents may significantly improve survival.

For polycythemia vera and essential thrombocytopenia, overall life expectancy may not be severely shortened, in view of the fact that they occur most frequently in older individuals.

If left untreated, patients with MPNs may die within months after the onset of symptoms.

References

  1. Ma X, Does M, Raza A, Mayne ST (2007). "Myelodysplastic syndromes: incidence and survival in the United States". Cancer. 109 (8): 1536–42. doi:10.1002/cncr.22570. PMID 17345612.
  2. Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J; et al. (2015). "Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia". Indian J Med Paediatr Oncol. 36 (1): 3–16. doi:10.4103/0971-5851.151770. PMC 4363847. PMID 25810569.